Literature DB >> 21372122

New and investigational treatments in cystic fibrosis.

Mangala Narasimhan1, Rubin Cohen.   

Abstract

Cystic fibrosis (CF) is an autosomal recessive disorder that affects approximately 1 in 3,000 Caucasian births, or 30,000 individuals in the US and 70,000 worldwide. The discovery of the CF gene, isolation of the CFTR protein and understanding of molecular mechanisms behind the clinical expression of CF are being translated into newer treatments. Treatments for CF and its manifestations are discussed in this article including inhaled antibiotics, hydrator therapies, anti-inflammatory agents and protein modifiers. New and experimental treatments that are in development are also discussed. Outcomes for these treatments are forced expiratory volume in one second (FEV(1)) improvement, CF-related quality of life, use of intravenous antibiotics and frequency of exacerbations and hospitalizations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21372122     DOI: 10.1177/1753465811398267

Source DB:  PubMed          Journal:  Ther Adv Respir Dis        ISSN: 1753-4658            Impact factor:   4.031


  5 in total

1.  Toll-like receptor 4 is not targeted to the lysosome in cystic fibrosis airway epithelial cells.

Authors:  Catriona Kelly; Paul Canning; Paul J Buchanan; Mark T Williams; Vanessa Brown; Dieter C Gruenert; J Stuart Elborn; Madeleine Ennis; Bettina C Schock
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-01-11       Impact factor: 5.464

Review 2.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

Review 3.  Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs-A Review.

Authors:  Ana Margarida Sousa; Maria Olívia Pereira
Journal:  Pathogens       Date:  2014-08-18

4.  Data Mining of Lung Microbiota in Cystic Fibrosis Patients.

Authors:  Jianguo Li; Chunyan Hao; Lili Ren; Yan Xiao; Jianwei Wang; Xuemei Qin
Journal:  PLoS One       Date:  2016-10-14       Impact factor: 3.240

5.  Targeting cytosolic proliferating cell nuclear antigen in neutrophil-dominated inflammation.

Authors:  Alessia De Chiara; Magali Pederzoli-Ribeil; Pierre-Régis Burgel; Claire Danel; Véronique Witko-Sarsat
Journal:  Front Immunol       Date:  2012-10-09       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.